ULTRAGENYX PHARMACEUTICAL INC.

Lobbying for ULTRAGENYX PHARMACEUTICAL INC. · Pharmaceuticals

Filing 3rd Quarter - Report

3rd Quarter (July 1 - Sep 30) 2025 · California · House · Senate · $140,000.00 expenses · posted Oct 17, 2025

Lobbying activity 3

Health Issues

Issues related to drug development, access and reimbursement for rare and ultra rare diseases.

Budget/Appropriations

Issues related to drug development, access and reimbursement for rare and ultra rare diseases.

Medicare/Medicaid

Issues related to drug development, access and reimbursement for rare and ultra rare diseases.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.